Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals is well positioned for growth because Illuccix provides a strong commercial base while the broader radiopharmaceutical platform adds multiple catalysts across diagnostics and therapeutics. The company’s pipeline is supported by compelling clinical data, including ITM-11’s median PFS of 23.9 months versus 14.1 months with everolimus and its lower Grade 3/4 treatment-related adverse events of 18% versus 40%, plus Pixclara’s first FDA-approved FET-PET indication for gliomas. Financially, ITM generated $273MM of revenue in 2025, $156MM in 1H26, and is expected to contribute about $106MM of annualized 2026 EBITDA, while combined pro forma 2026 revenue and other income may exceed ~$1.3B.

Bears say

Telix Pharmaceuticals is exposed to significant execution risk because the valuation depends heavily on uncertain pipeline success, including only 10%, 35%, and 65% approval probabilities for TLX591/TLX592 across key prostate cancer settings. Its $6.66B estimated market value relies on Illuccix and Gozellix carrying the revenue base, while future upside from Zircaix is still only risk-adjusted and contingent on 95% probability assumptions. The negative outlook is reinforced by explicit risks of clinical setbacks, regulatory delays or failures, competitive pressure, inability to meet sales estimates, and long-term dilution risk.

TLX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 3 analysts, TLX has a Strong Buy consensus rating as of Oct 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.